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Ethyldeshydroxy-sparsomycin (EdSm) is a rlbosomal pro­
tein synthesis Inhibitor which synerglstically enhances the 
antitumor activity of cisplatin against L.1210 leukemia In 
vivo. Because cellular glutathione (GSH) and glutathione S- 
transferases (GST) are reported to interfere with the anti- 
tumor activity of cisplatin, we analyzed the effect of EdSm 
and cisplatin on GSH and GST activity in selected tumor 
cells. For this purpose we used three murine leukemia 
tumors with different sensitivities towards EdSm and 
cisplatin: L1210-WT, sensitive to both drugs, L1210-Sm, 
resistant to EdSm, and L1210-CDDP, resistant to cisplatin. 
No significant differences were detectable between these 
three cell lines regarding the population doubling time, the 
cell size, and the cellular level of protein and glutathione. 
Neither of the resistant L1210 subclones showed P-glyco- 
protein expression. Drug exposure, however, changed the 
Intracellular dynamics. Exposure to EdSm strongly de­
creased the amount of cellular protein, decreased the 
overall GST activity and led to GSH depletion, whereas 
exposure to cisplatin induced a rise in the amount of 
protein, in GSH, and In the total GST activity. These effects 
are dose-dependent and correlate well with the sensitivity 
of the tumor cells for EdSm or cisplatin. In addition, 
exposure to EdSm lowered the of GST in L121Q-WT 
and L1210-Sm; however, In L1210-CDDP both the VmQX and 
the Km were Increased. That this was not a direct effect of 
EdSm on GST was shown in a cell-free system, where 
EdSm did not Influence the GST activity nor could It act as 
a substrate for GST. Our results suggest that the synergis­
tic combination of EdSm and cisplatin might be explained 
by EdSm switching off the cellular detoxification mechan­
ism for cisplatin, i.e. by Inhibition of de novo synthesis and 
subsequent depletion of GSH and GST.
Key words: Cisplatin, drug-resistance, glutathione S- 
transferase, glutathione, sparsomycin.
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Ethyldeshydroxy-sparsomycin (EdSm) is a potent 
inhibitor of ribosomal protein synthesis1 and is one 
of the sparsomycin analogs which show enhanced 
antitumor activity in comparison to sparsomycin.2 In 
addition» EdSm synergistically enhances the anti­
tumor activity of cisplatin In vivo  in mice bearing 
LI 210 leukemia tum or cells sensitive to both drugs3 
but is unable to do so w hen  these tumor cells are 
resistant to one of these drugs/1 The in vitro 
sensitivity of LI 210 leukemia cells correlates well 
w ith  the antitumor activity of EdSm and cisplatin in 
v iv o , The cellular factors of these leukemic tumors, 
which are responsible for the enhanced chemosensi- 
tivity to combined drug treatment, are unknown. 
Likewise, it is not know n for these leukemic cell 
lines w hich  mechanism is* involved in cisplatin 
resistance or EdSm resistance.
Glutathione, a tripeptide containing a sulfhydryl 
group, protects cells from oxidative damage, partici­
pates in the transport of amino acids, and is a 
cofactor for ribonucleotide reductase, which is 
required for deoxyribonucleotide synthesis. Gluta­
thione conjugation, established by a family of glu- 
tathione-S-transferases (GSTs), provides a defense 
mechanism because it removes potentially toxic low- 
soluble and/or eleetrophilic compounds by convert­
ing them into better water-soluble and non-electro- 
philic conjugates, A logical but undesirable effect of 
glutathione therefore is its potential involvement in 
cellular resistance after long or repeated exposure to 
anticancer agents. Tumor cells may adapt to chemi­
cal or nutritional depletion of GSH by producing a 
rebound elevation of GSH levels and the induction 
of elevated levels of specific GST iso-forms. Cellular 
concentrations are maintained by cle novo  synthesis 
of GSH from the constituent amino acids, using the
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enzymes r-glutamyl cysteine synthetase and glu­
tathione synthetases. A num ber of reports describe months, 
an elevated level o f glutathione in tumor cells, w hich 
are resistant to cisplatin ,5 ~8 but a decreased cisplatin
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are stably resistant in drug-free media for up to 6
uptake 9.10 and increased DNÀ repair have been Drugs
reported as well, resulting in less DNÀ interstrand
11 — 13 Moreover, the activity of GST in EdSm was synthesized at the Department of Organiccross-links.
cisplatin-resistant tum or cells is often increased com­
pared to cisplatin-sensitive tumor cells.11115 GSH 
depletion can increase the chemosensitivity to
5 ( 16_‘IBcisplatin ’v or partially reverse cisplatin resis­
tance .19 On the other hand, conflicting results were 
obtained upon in v ivo  glutathione depletion using
Chemistry (University of Nijmegen, The Nether­
lands)1 and was acquired in a lyophilized form. The 
drug was dissolved in phosphate buffered saline 
(PBS, pH 7.4) and kept in dark flasks at 4°C. 
Cisplatin was kindly provided by Pharmachemie 
(Haarlem, The Netherlands). Solutions with the 
DL-buthionine sulfoximine (BSO). One report foiled required drug concentration were prepared just
to observe an increase of the antitumor activity of before administration by dilution with isotonic NaCl.
20cisplatin, yet another report showed an increase in
sensitivity to cisplatin .1 EdSm, being a potent
inhibitor of ribosomal protein synthesis, might in- Drug treatment
hibit cle novo  synthesis of enzymes like GST and of
enzymes needed for glutathione synthesis, thereby The L1210 leukemia cells were seeded and allowed
potentiating the antitum or activity of cisplatin. to grow in a fresh, drug-free medium for 24 h.
In this study w e addressed these questions using Thereafter, EdSm or cisplatin were applied in in-
three murine leukemia tumors which show signifi- creasing concentrations from 0.01 to 30 fxM for a
cant differences in cytotoxic IC50 levels for EdSm or period of 20 h. To investigate the effect of drug 
cisplatin, and great differences in antitumor re- exposure on enzyme kinetics of GST the tumor cells
sponses. The mechanism responsible for these 
sensitivity differences is unknown. Therefore, infor­
mation about cellular changes in tumor cells after
were exposed to 30 /¿M EdSm during 4 h. After drug 
exposure, the tum or cells were washed twice with 
PBS and used for different assays. The cell viability
EdSm exposure could be very valuable in order to was checked by  dye exclusion using Trypan blue 
predict the chemomodulatorial antitumor activity of and the cell num bers were determined using a 
EdSm in drug combinations and possibly for o ther hemocytometer. All experiments were performed in
protein synthesis inhibitors as well. In an attempt to 
explain the  patterns of synergistical drug inter- 
actions in these leukemic murine tumors w e investi­
gated the dynamics of a panel of cellular parameters: 
protein content, GSH and GSSG content, and GST 
activity.
triplicate.
Cytotoxicity assays
Materials and methods
Cell culture
The culture conditions for murine 11210 leukemia 
cells have been described earlier.1 The murine 
LI210 leukemia wild-type (L12I0-WT) and the cis­
platin-resistant subclone (L1210-CDDP) w ere kindly 
supplied by Dr G Atassi (Institute Jules Bordet, 
Laboratory for Experimental Chem otherapy Brus­
sels, Belgium). We have established another sub­
clone of the  mouse tum or cell line L1210 with 
acquired resistance to sparsomycin by repeated in  
vivo  treatm ent w ith increasing doses of deshydroxy- 
sparsomycin (L1210-Sm). In  vitro  these subclones
The clonogenic ability of drug-treated cells was 
evaluated by a soft-agar colony assay Leukemic 
colonies w ere  grow n by plating the cells in 0 .3% 
agar in six-well plates (Costar) in a drug-free med­
ium. After 8 days of incubation, colonies (greater 
than 50 cells) w ere  scored using an inverted micro­
scope. The surviving fraction was calculated by 
dividing the absolute survival (number of colonies) 
of the treated sample by the absolute survival of a 
parallel control sample. Each experimental point 
was determined in duplicate and all experiments 
were repeated twice.
Flow cytometry
Cell cycle distributions, Single-celi preparations 
were obtained from  control cultures and lixed in
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70% ethanol. The cells w ere removed from the 
fixative by centrifugation and washed with PBS, The
stained in 400 u\ PBS containing
nated ceil liomogenates with the lluorometric 
method of Hissin and Hilf using o-phthalaldehyde.
were
GST
20 fig /m l  propidium iodide and were measured with 
a flow cy tome ter 5 OH (Ortho Instruments, Weat- 
wood, CA). Red fluorescence, for DNA content
measurement, was detected  through a 630 nm long GST catalyses the transfer of the -SI I group of 
pass filter and photomultiplier pulses were amplified glutathione to specific substrates. The activities of 
linearly. GSH transferases were measured at 25°C spectro- 
photometrieally with L-chloro-2,4-din it mbenzene 
(CDNB) as a substrate according to the procedure of
1
The conjugate, GDNB -glutathione, has an
P-glycoprotefn (Pgp)- For flow-cytometric analysis of 
Pgp expression, tumor cells w ere labeled with the 
Pgp-specific monoclonal antibody MRK16 (a gift absorbance band at 340 nm and the activity of the
enzyme can therefore be estimated by measuring thefrom Professor T Tsuruo) according to the method 
of Haniada/ 1 Thereafter, cells were stained with 
fluoresceinated rabbit anti-mouse IgG (Dakopatts, 
Glostrup, Denmark), FITC-“RAM~F(ab')2 fragments 
1:50 diluted in PBS. Cells stained with FITC were
kinetics of the change in optical density at this 
wavelength, Assays were performed in 100 mM 
potassium phosphate, pH 7.4, 1 mM EDTA, 5 mM 
GSH, 1 mM CDNB and 0,1 mg/ml cytosolic protein,
analyzed by flow cytometry using a 515/530 band- Michaelis-Menten kinetics of cytosolic GSH trans­
pass filter. The area of the green fluorescence signal 
and both area and peak value of the red fluorescence 
signal were recorded in list mode and analyzed with 
a PDP11/34 computer (Digital Equipment, Galway, 
Ireland).
ferases of sonicated cells were measured using 
CDNB as a substrate. GSH concentrations in the 
assay system were fixed at 1 mM. The Km and 
were calculated using the Lineweaver-Burk plot.
Cell size, Flow cytometry of the samples was done 
with a cytofluorograph equipped with on-line com­
puter analysis. The exact relationship between
Statistics
scattered light and cell size is difficult to quantify. It 
depends on the light collection, angle, aperture and 
index of refraction of the suspending fluid. Usually, 
however, the scattered light increases mono ton ically 
with the cell volume. In this study, latex micro­
spheres of 10 and 20 ftm  w ere used to calibrate any 
differences in cell size betw een these three cell 
lines, All samples were light-mieroscopically checked 
for differences in size.
A comparison of the different sample distribution is 
usually performed on the log-scale in order to reduce 
skewness, be more robust against outliers or make 
the SDs more comparable, liven if this transforma­
tion to the log-scale seems unnecessary—as in this 
study—there is hardly any harm in doing so. 
Differences betw een the means of different groups 
were compared using the analysis of variance
(ANOVA) in combination with the Ryan multiple /•- 
test. All computations w ere done by SAS, proc, 
ANOVA. The results have been expressed as the 
mean ±  SE and p  <  0,05 was considered to be 
significant,
Protein
For an estimation of the amount of protein we used 
the lluorometric assay of lldenfriend / 2 as modified 
by Lai/* Bovine serum albumin was used for 
calibration.
Results
Biological characteristics of the L1210 
leukemia cell lines
Glutathione
Glutathione consists o f tw o forms, reduced (GSH) 
and oxidized (GSSG), and can be determined by 
established enzymatic techniques / 1 Cellular glu-
tathione content was determined from the deprotei-
IC50 levels of the various cell lines for EdSm and 
cisplatin are compiled in Table 1. The cisplatin- 
resistant L1210 line (LI 210-01)DP) acquired some 
resistance to EdSm as well, resulting in a resistance 
factor of 4 compared to 18 in 1,121O-Sm. Yet, the 
L'1210-Sm has normal sensitivity for cisplatin. No 
detectable, significant difference was found between
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Table 1. Characteristics of three different murine leukemia cell lines, with regard to population doubling times, 
expression of plasma membrane Pgp, and sensitivity for EdSm and cisplatin during exponential cell growth [cell lines 
are wild-type (L1210-WT), cisplatin resistant (L1210-CDDP) and deshydroxy-sparsomycln resistant (L1210-Sm)]
Parameter L1210-WT L1210-CDDP L1210-Sm Unit
T doubling timea 13.6 ±  1.2b 13.2 ± 1.4 13,9 ±  1.2 h
Relative cell diameter 1.0 ±0,17 1.0 ±0,17 1.2 ±0,17
Pgp <  1 < 1 2,2 % positive cells
IC50 EdSm0 0.22 ±  0,08 0,88 ±  0,16 4.0 ±  1,4 /¿M
RF EdSmd 1 4 18
IC50 CDDP 2,0 ±  1.25 3,8 ±  0.3 1,5 ±  0,2 fM
RFCDDP 1 1.9 0.75
aBased on 40 analyses for each cell line. 
bMean ±  SE.
CIC50 is the drug concentration needed during an exposure time of 20 h to give 50% growth inhibition in a colony-forming assay. 
dRF is the resistance factor, representing the fold increase in IC5o for a specific drug in a resistant cell line relative to the wild-type.
the three cell lines regarding population doubling phase cells is signiiicantly higher than that of LI2 10-
times, cell diameter and Pgp expression. Only the vSm cells, values which are 62.3 and 49.4%, respec-
cisplatin-resistant cell population harbors a few posi- tively. Moreover, the percentage of L1210-CDDP cells
live cells (2.2%). However, the intensity of their (6.8%) in the G2M phase is low compared to these
fluorescence was low  as a consequence of which values of L1210-WT ( 11,6%) and LJ210-Sm (12.7%)
w e ignored this information. Whilst the population cells. The percentage of Gi phase cells is not
doubling time is the same for all three cell lines, the significantly different within the three cell lines,
analysis of the cell phase distribution during expo- Furthermore, no difference was found in the average
nential grow th (Table 2) revealed significant differ- protein content of these cell lines (Table 3). The
ences ( p  =  0 .03) w ith  respect to the number of average glutathione levels in the resistant cell lines
cells in the S phase. To be more specific, the also did not change significantly: p  =  0.35 for GSH
percentage of L1210-CDDP tumor cells in the S oxidized, p  =  0.48 for GSSG and p  — 0.32 for total
Table 2. Cell phase distribution of the three L1210 cell lines, during exponential 
cell growth in tissue culture, in the absence of any drug treatment (the p value is 
calculated by ANOVA in combination with the Ryan multiple F-test)
Cell phase L1210-WT(10) L1210-CDDP (4) L121Q-Sm (12) p value
Gi 35.3 ±  6,6 31.0 ±2 .8  37.9 ±1 .8  0.19
S 53.1 ±  2.6 62.3 ±  3.0 49.4 ±  2.1 0.03
G2M 11,6 ±5 .3  6,8 ±1 .4  12.7 ±0 .9  0.07
Table 3. Standard values in three different murine leukemia cell lines for the protein content, the specific activity of 
GST using 1 mM CDNB as a substrate and the glutathione levels during exponential cell growth (the p value is 
calculated by ANOVA in combination with the Ryan multiple F-test)
Parameter L1210-WT L1210-CDDP L1210-Sm Unit p value
Protein 43.8 ±  4.8 (8)a 47.5 ±  2.3 (6) 39.5 ±  3.2 (6) /tg/106 cells 0.30
GST 2.09 ¿0.15 (9) 1.84 ±  0.13 (7) 2.36 ±  0.15 (7) nmol/min/106 cells 0.09
GST 49.4 ±  5.0 (9) 38.2 ±  1.7 (7) 58.0 ±  5.9 (7) nmol/min/mg protein 0.04
GSH 331 ±  55 (8) 371 ±  46 (7) 268 ± 46 (7) ng/106 cells 0.35
GSSG 165 ±  26 (8) 188 ±  23 (7) 145 ±  19 (7) ng/106 cells 0.48
Ratio GSH/GSSG 2.0 ±  0.2 2.0 ±  0.2 1.9 i  0.2
Total-GS 496 ±  74 (8) 560 ±  56 (7) 413 ±  58 (7) ng/106 cells 0.32
°Mean ±  SE, (n) is number of experiments.
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glutathione (Table 3). Moreover, a 2:1 molar ratio 
between GSH and GSSG was found in all cell lines.
drug treatment with cisplatin or EdSm and the 100% 
control level were statistically analyzed. The curves
The specific GST activities are different (Table 3). In of L1210-WT and L1210-CDDP are significantly differ- 
particular, if we compare the L1210-Sm with the ent, p  ~  0.04 and 0.05, respectively Worth mention- 
L1210-CDDP cell line, w e notice an elevated level of ing is the situation in L1210-Sm, in which EdSm 
58 versus 38.2 nm ol/m in/m g protein, respectively exposure only caused a moderate effect, while 
(ƒ> =  0.04), or 2.36 and 1.84 n m o l/m in /106 cells, cisplatin had no effect at all (ƒ)== 0.45). Comparable 
respectively (/; =  0,09). effects w ere observed for GST activity, Because we
are interested in the total effect per tumor cell, we 
decided to express the values for the glutathione 
level and GST activity in units per 10° cells instead 
of mg protein. The effect of both drugs on the 
overall cellular GST activity is represented in Figure 
2. These results parallel the effects observed for the 
The dose-eflect curves for cisplatin and EdSm intracellular protein level, but significant differences 
diverge in all three cell lines. Inhibition of the betw een EdSm and cisplatin were found only in the 
protein synthesis by EdSm has a strong impact on L1210-WT cell line (/> =  0 .0 i), while the effect in
Effects of EdSm and cisplatin on the 
intracellular protein and glutathione 
levels and on the GST activity
the cellular protein content (Figure 1). EdSm causes the L1210-CDDP cell line conies close to significance
a dose-dependent decrease in protein level, which is (p  =  0,06). Thus, the decrease in GST activity (when
most extensive and most rapid in LI210-WT, and treated w ith  EdSm) parallels the decrease in total
already starts at submicromolar EdSm eoncentra- protein. Similarly the increase in GST activity (when
tions. This decrease is more gradual in L1210-CDDE treated w ith  cisplatin) follows the increase in p ro
L1210-Sm is clearly less sensitive and requires at tein content. This implies that if the specific activity
least 10 ¿¿M to see the same effect. Cisplatin causes of GST was expressed in nm ol/m in/m g protein, no
the opposite effect, i.e. a dose-dependent increase in significant differences are found in these cell lines
protein level in the L1210-CDDP and L1210-WT cell neither betw een EdSm and cisplatin treatment, nor
lines with little effect on L1210-Sm. The curves of betw een drug-treated and control cells.
%  Proteln/106 cells
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0
0.1 0.3 1 3
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m L1210-WT
♦ L1210-CDDP
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o L1210-CDDP
o L1210-SM
Drug concentration (/«M)
Figure 1. Relative protein content (ng/106 cells) of three 
different murine leukemic tumors after 20 h exposure to 
varying doses of EdSm (open symbols) or cisplatin (solid 
symbols).
% GST actlvlty/10 0 cells
■ L1210-WT
♦ L1210-CDDP
•  L1210-SM
a L1210-WT
o L1210-CDDP
o L1210-SM
Drug concentration (//M)
Figure 2. Relative cellular activity (nmol/min/10B cells) 
of GST in three different murine leukemic tumors after 
20 h exposure to varying doses of EdSm (open symbols) 
or cisplatin (solid symbols).
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Effects of EdSm and cisplatin on the 
intracellular glutathione dynamics
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Figure 3 shows the results of drug treatment on the 
intracellular glutathione level in these leukemic 
tumors. Again, EdSm and cisplatin showed opposite 
effects in these three cell lines, and again these 
effects are dose- and cell line-dependent. Significant 
differences have only been  observed in the L1210- 
WT cell line ( p  — 0.05). Only about 3 /¿M was 
required to induce strong GSH depletion in L121.0- 
WT. In the sp a rsomyc in-resist ant tumor 3 /iM EdSm 
evoked a 50% increase in GSH level and a significant 
decrease was only observed at 30 ¡ttM. In the 
cisplatin-resistant tum or the GSH depletion dropped 
with EdSm by 3 /¿M or greater, albeit slowly com­
pared to the wild-type. The effect of cisplatin 
treatment on the GSH levels followed the same 
pattern as seen w ith  GST and protein.
Enzyme kinetics
First we investigated w hether  EdSm and cisplatin 
could directly affect the  activity of GST or the assay. 
The results in a cell-free system (Table 4) indicate 
that only a very high dose of cisplatin provides a
% Glutathione/106 cells
■ L1210-WT
♦ L1210-CDDP
• L1210-SM
□ L1210-WT
o L1210-CDDP
o L1210-SM
Drug concentration (/*M)
Figure 3. Relative cellular glutathione level (ng/106 
cells) in three different murine leukemic tumors after 20 h 
exposure to varying doses of EdSm (open symbols) or 
cisplatin (solid symbols).
Table 4. Influence of EdSm and cisplatin on the GST 
activity in a cell-free system relative to untreated control 
(4-CDNB) in the presence (+CDNB) or absence 
(-CDNB) of substrate (1 mM CDNB)
Drug dose
(/<M)
EdSm Cisplatin
-CDNB +CDNB CDNB -CDNB
30
10
0.0a
0,0
99.2%
97.9%
0.0
0.0
102% 
69%
aThe enzyme activity of GST (nmol/min/mg protein) is ex­
pressed as percentage of the treated sample over the +CDNB 
control (%T/C).
lower value, but we do not know w hether this is 
due to inhibition of the enzyme, a low substrate 
potential or interference with the assay (e.g. reaction 
with GSH, CDNB or the product). We did not pursue 
this any further since, under our standard conditions 
(30 ftM or lower), no effect was observed and the 
intracellular-free concentrations of CDNB will cer­
tainly not reach the 10 mM level. The next question 
we addressed was w hether EdSm could interfere 
with intracellular GSH transferases. We therefore 
used the Michaelis-Menten kinetics to estimate the 
K,11UX and K m of cellular GST in the presence of 
30 ¿iM EdSm for a period of 4 h. These results are 
summarized in Table 5. In the control situation we 
saw a significant difference in VnvAX between LI 210- 
CDDP (150 nm ol/m in/m g protein) and the other 
cell lines, .LI 210-WT (107 nm ol/m in/m g protein) 
and L1210-Sm (95 nm ol/m in/m g protein). This is 
even more pronounced for the Km values. The Km 
value for CDNB in the IJ210-CDDP cell line is 
almost 3“loId higher than that of LI 210-WT and 
L1210-Sm. Exposure to EdSm reduced the maximal 
activity on a protein base in L1210-WT and L1210- 
Sm, although not significantly, and increased the 
Vtmx in L1210-CDDP cell lines. These EdSm effects, 
however, were not significant, which is in part due 
to the small sample number.
Discussion
At the onset of our study no information was 
available about the mechanisms underlying resis­
tance against cisplatin in L1210-CDDP and against 
EdSm in LI 210-Sin. Our results show (Table 1) that 
these three leukemic tumor cell lines are compar­
able as to the population doubling time and cell size. 
Also, the protein content and total glutathione level 
are similar in these cell lines (Table 3). The GST
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Tables. Effect of 4 h incubation with 30 //M EdSm on Michaelis-Menten 
parameters of GST in the various L1210 cell lines (see Materials and methods)
Hffecfs o f  e(bylclcsbydn)X)'-s[Hirsoniy'c/n on GSH and  GST
L1210-WT L1210-CDDP L1210-Sm p value0
V  b Vmax control 
±  EdSmc 
p valued
107 ±  23 (3) 
77 ±  19(3) 
0.34
150 ±  10 (3) 
131 ±41  (3) 
0.63
95 ±  25 (2) 
72 ±  15 (2) 
0.35
0.28
0.39
is e 
A  m control 
+  EdSmc 
p value01
0.62 ±0.12 (3) 
0.66 ±  0,08 (3) 
0.65
1.52 ±0 .34  (3) 
2.61 ±  1.05 (3) 
0.78
0.58 ±0 .13  (2) 
0.52 ±  0.01 (2) 
0.18
0.06
0.24
ap value given for one-way ANOVA between cell lines. 
bnmol/min/mg protein.
C%T/C (treated over control).
d p value given for the contrast between the control group and the treated group. 
QmM,
activities, however, are statistically significantly dif­
ferent. The GST in L1210-CDDP also shows a 
relatively high K m. To explain these results, we 
should bear in mind that the GSTs are a multigene 
family of isoenzymes which catalyze the reaction 
betw een numerous electrophilic compounds and 
glutathione.27,28 The cytosolic GST is divided into
significant elevation of the Pgp level. Hence, we 
conclude that resistance towards EdSm does not 
involve Pgp,
As for glutathione, our results show  that EdSm is 
not a likely target for GSH conjugation, since EdSm 
did not directly influence the GST activity (Table 4). 
Exposure of intact tum or cells to EdSm yielded a
four gene families: the a, /t, n  and 0 class. The n- dose- and cell line-dependent decline in cellular
class is preferentially expressed in tumor cells. They protein content, glutathione level, as well as in the
function as dimers, with heterodimers occurring in total GST activity. This dose-dependency of the2o
the same class. The various classes have different decline in protein content in the individual cell lines 
specific activities and different substrate specificity. upon EdSm treatment correlates directly with the 
We have measured the overall cellular GST pool and 
the differences w e observed between the cell lines
most likely indicate a substantial variation at the 
isoenzyme level. Another difference between these 
cell lines was detected in the cell phase distribution.
L1210-CDDP cells contain more S phase cells and 
less G2M cells than L1210-WT and. L1210-Sm, which 
indicates a prolonged S phase, probably due to 
enhanced DNA repair. Another parameter often 
involved in resistance to chemotherapy is the 
elevated expression of a Pgp of 170 kDa, which acts 
as a broad spectrum membrane pum p and removes which could cause effects such as depletion of GSH
sensitivity of each cell line for EdSm! Under normal 
conditions the cellular level of a protein is deter­
mined by the balance between the rates of its 
synthesis and degradation. The average turnover 
times for individual proteins range from several 
minutes to months or even years/ 2 Many intracellu­
lar proteins that have half-lives of 10 min or less are 
proteins with key regulatory roles whose cellular 
level is rapidly regulated by modulating their rate of 
synthesis." Inhibition of protein synthesis by EdSm 
will directly disturb short-lived protein balance,
chemotherapeutic drugs as well. Although Pgp ex and GST. The cellular glutathione level is maintained
pression has never been implied in cisplatin resis- by de novo synthesis of GSH from the constituent
tanec, other antitumor agents have been shown to 
be able to induce Pgp expression in murine leuke­
mic cells.30 Even alkylating agents, like mitomycin C, 
can induce resistance in L'l 210 leukemia cells 
through changes in the membrane Pgp population / 1 
but these tumor cells remain sensitive to cisplatin. A 
possible Pgp induction by Sm derivatives has not yet
amino acids, using the enzymes r-glulamyl cysteine 
synthetase and glutathione synthetase. Furthermore, 
glutathione cycles betw een a reduced thiol form 
(GSI1) and an oxidized form (GSSG) in which two 
GSH tripeptides are linked by a disulfide bond, and 
1 cun be reduced to GSH by glutathione 
reductase .31 Because GSH is non-ribosomally syndic-
GSSG a
been investigated. Our results show what w e ex- sized, depletion of GSH must be caused by inhibition 
pected, i.e. that the cisplatin-resistant LI 210 sub- of the synthesis of these enzymes. Because glu-
clone shows 110 Pgp induction. The sparsomyein- 
resistant LI 210 cell line also does not show  a
tathione depletion parallels the declining protein 
content, EdSm apparently has a strong effect on
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these enzymes w hich  also implicates that these Acknowledgments 
enzymes have relatively short turnover times and
HP Hofs e t al.
require a high level of de m w o  synthesis. The antibody MRK16 was kindly supplied by Profes-
In combined chem otherapy we must be cautious sor TTsuruo, University of Tokyo, Japan.
not to interpret many of the effects as the result of 
simple direct interaction betw een cytostatic agents. 
As this study has also shown, administration of 
cisplatin can cause the induction of endogenous 
GSH synthesis, as well as enhanced levels of 
enzymes such as GST which can catalyze the 
detoxification of agents such as cisplatin.35 GSH 
depletion by BSO suggests two roles for GSH in 
cisplatin resistance, i.e. cytosolic elimination, result­
ing in less DNA platination, and a nuclear effect on 
the formation and repair of DNA platinum adducts; 
Cisplatin can also conjugate non-enzymatic with 
sulfhydryl com pounds like glutathione; This 
reaction involves nucleophilic displacement o f chlor­
ide ligands, either directly or subsequent to a 
reaction with water. This type of reaction could 
explain the apparent reduction in GST activity that 
w e observe at very high cisplatin concentrations. In 
addition to GSH, o ther thiols, like the metallothio- 
neins (MT), can act as a nucleophile towards 
electrophilic agents like cisplatin, but the involve­
ment of MT in acquired resistance to cisplatin is 
rather controversial. ” “ In the murine leukemia 
cell line L121Q, the degree of resistance was 
reported to be associated with the level of MT;9 
however, in another study the resistance o f LI 210- 
CDDP cell towards cisplatin could neither be based 
on an increased level of MT nor on an enhanced 
ability to increase the synthesis of MT after cisplatin 
exposure .11 Thus, MT may be associated with the 
induction of cisplatin resistance, but its causal role 
remains to be established. It should be noted that 
resistance to cisplatin is a relative term, which is at 
least partially attributable to its narrow therapeutic 
index. Because o f fatal toxicity, it is often not 
possible to successfully treat tumors, which exhibit 
even a small inherent resistance to cisplatin, by 
increasing the dose level of cisplatin, As a conse­
quence, combination therapy with an agent like 
EdSm, which enhances cisplatin’s anti tumor effects 
with little or no enhancem ent of cisplatin‘s 
toxicity/ ’ may be of value in the treatment of 
tumors which resist treatm ent with cisplatin alone.
To summarize, our results suggest that the syner­
gistic combination of EdSm and cisplatin can, at least 
partly, be explained by the EdSm-induced block of 
protein synthesis, w ith subsequent depletion of the 
cellular detoxification mechanism for cisplatin, and 
will very likely Involve a reduction in the intracellu­
lar level of GSH.
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